AvalehtTMOS34 • BVMF
add
Thermo Fisher Scientific BDR
Viimane sulgemishind
52,00 R$
Tänane vahemik
52,00 R$ - 53,89 R$
Aasta vahemik
44,30 R$ - 74,45 R$
Turuväärtus
181,05 mld USD
Keskmine maht
20,74 tuh
P/E suhe
-
Dividendimäär
-
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Käive | 10,86 mld | 2,98% |
Põhitegevusega seonduv kulu | 2,48 mld | −1,47% |
Puhastulu | 1,62 mld | 4,46% |
Puhaskasumimarginaal | 14,90 | 1,43% |
Puhaskasum aktsia kohta | 5,36 | −0,19% |
EBITDA | 2,62 mld | −0,04% |
Tõhus maksumäär | 5,38% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 6,39 mld | −27,58% |
Kogu vara | 101,23 mld | 2,78% |
Kõik kohustused | 50,63 mld | −0,66% |
Kogu omakapital | 50,60 mld | — |
Emiteeritud aktsiate arv | 377,61 mln | — |
Hinna ja väärtuse suhe P/B | 0,39 | — |
Varade tasuvus | 4,84% | — |
Kapitali tasuvus | 5,71% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | juuni 2025info | Y/Y muutus |
|---|---|---|
Puhastulu | 1,62 mld | 4,46% |
Põhitegevuse rahakäive | 1,40 mld | −28,62% |
Investeeringute raha | −288,00 mln | −13,83% |
Finantseerimise raha | −991,00 mln | −761,74% |
Raha ja raha ekvivalentide muutus | 431,00 mln | −72,69% |
Tasuta rahavoog | 736,12 mln | −44,08% |
Teave
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain. Wikipedia
Tegevjuht
Asutatud
1956
Veebisait
Töötajate arv
125 000
